Potential Therapeutic Relevance For TIM-3 In Breast Cancer Patients

Since the first FDA approval of an immune checkpoint blockade (ICB) therapy in 2011, immunotherapy has increasingly become a standard-of-care treatment for cancer. ICB can…
Read more